Annual Drug Patent Expirations for EMTRIVA
Emtriva is a drug marketed by Gilead and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for EMTRIVA.
The generic ingredient in EMTRIVA is emtricitabine. Two suppliers are listed for this compound. Additional details are available on the emtricitabine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
